EXTON, Pa.--(BUSINESS WIRE)-- BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that, nine months after commercial availability in the US, Regeneron’s Eylea captures 13 percent of wet age-related macular degeneration (AMD) patient share, although patient shares for Genentech’s Avastin and Lucentis have remained relatively stable compared to one year ago. Considering the importance of cost in this market, it is not surprising that Avastin is the first-line approach preferred by the majority of ophthalmologists. However, current Eylea prescribers administer Avastin to significantly fewer patients compared to non-prescribers, and consider the cost to the patient as being less influential in their prescribing decisions compared to non-prescribers. Despite its recent availability, Eylea is considered to be a preferred second- and third-line treatment approach for wet AMD among the greatest percentage of respondents, with uptake driven largely by its perceived dosing schedule convenience. Ophthalmologists do anticipate Avastin and Lucentis shares to contract significantly over the next six months as Eylea’s trial and use continues to increase.
The recently published TreatmentTrends®: Age-Related Macular Degeneration (US) report finds that, although the majority of physicians consider there to be a high unmet need for new products to treat AMD, both unaided and aided awareness of products in development is low. Aided awareness among physicians is highest for products in development for wet AMD, primarily Ohr Pharmaceutical’s Squalamine (45 percent), followed by Ophthotech’s Fovista (39 percent) and GlaxoSmithKline’s pazopanib (29 percent). Fovista and Squalamine are considered by respondents to be the products which would bring the most potential value to their practice / patients, largely due to Fovista’s promising clinical data and Squalamine’s eye drop administration. Few physicians are aware of products in development for dry AMD, specifically Alcon’s AL-8309B, MacuCLEAR’s MC-1101 and Otsuka / Acucela’s ACU-4429, despite the lack of treatment options for this disease. Indeed, ophthalmologists report that the majority of dry AMD patients are currently being managed with observation only or vitamins and nutritional supplements, although use of these products is an area of controversy in the treatment of dry AMD.
TreatmentTrends®: AMD (US) is an annual syndicated primary market research report series that provides a comprehensive view of the current and expected future management of AMD, with a focus on wet AMD. The survey was fielded in mid-August 2012 with 70 board-certified retinal specialists and 30 board-certified general ophthalmologists. TreatmentTrends®: AMD (US) covers the use of treatment approaches and pharmacotherapy agents for the treatment of dry and wet AMD, as well as attitudes and perceptions toward these products, advantages and disadvantages, ideal patient types, barriers to growth and expected future use. In addition, respondents were queried about their awareness of and interest in products in development for the treatment of dry AMD or wet AMD.
About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com. BioTrends is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
Source: BioTrends Research Group